CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

NCT04091737 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Unanticipated delays, not for safety reasons

Conditions

Anemia, Sickle Cell

Interventions

BIOLOGICAL: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734

Sponsor

CSL Behring